Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2020 | 2 |
2021 | 1 |
2023 | 3 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1.
Lancet. 2023.
PMID: 37015244
Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators.
Rheault MN, et al.
N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3.
N Engl J Med. 2023.
PMID: 37921461
Clinical Trial.
Item in Clipboard
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators.
Rovin BH, et al.
Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3.
Lancet. 2023.
PMID: 37931634
Clinical Trial.
Item in Clipboard
[Clinical importance and diagnostic methods of minimal hepatic encephalopathy].
Stawicka A, Zbrzeźniak J, Świderska A, Kilisińska N, Świderska M, Jaroszewicz J, Flisiak R.
Stawicka A, et al. Among authors: zbrzezniak j.
Pol Merkur Lekarski. 2016 Feb;40(236):117-21.
Pol Merkur Lekarski. 2016.
PMID: 27000818
Review.
Polish.
Item in Clipboard
Brain-derived neurotrophic factor as a potential diagnostic marker in minimal hepatic encephalopathy.
Stawicka A, Świderska M, Zbrzeźniak J, Sołowianowicz N, Woszczenko A, Flisiak R, Jaroszewicz J.
Stawicka A, et al. Among authors: zbrzezniak j.
Clin Exp Hepatol. 2021 Mar;7(1):117-124. doi: 10.5114/ceh.2021.103242. Epub 2021 Feb 2.
Clin Exp Hepatol. 2021.
PMID: 34027124
Free PMC article.
Item in Clipboard
Clinical Usefulness of the Inhibitory Control Test (ICT) in the Diagnosis of Minimal Hepatic Encephalopathy.
Stawicka A, Jaroszewicz J, Zbrzeźniak J, Sołowianowicz N, Woszczenko A, Świderska M, Flisiak R.
Stawicka A, et al. Among authors: zbrzezniak j.
Int J Environ Res Public Health. 2020 May 22;17(10):3645. doi: 10.3390/ijerph17103645.
Int J Environ Res Public Health. 2020.
PMID: 32455895
Free PMC article.
Item in Clipboard
Pure Red Cell Aplasia and Antibody-Mediated Rejection: Double Trouble in 1 Kidney Transplant Recipient Solved by Intravenous Immunoglobulin Infusion: A Case Report.
Knysak M, Napora M, Misiukiewicz-Poć M, Pawłowska A, Kwella N, Zbrzeźniak J, Winiarska A, Stompór T.
Knysak M, et al. Among authors: zbrzezniak j.
Transplant Proc. 2020 Oct;52(8):2530-2532. doi: 10.1016/j.transproceed.2020.01.091. Epub 2020 Apr 8.
Transplant Proc. 2020.
PMID: 32276841
Item in Clipboard
Cite
Cite